Shrinks In Sneakers

Tag: Doctor

  • Natural ADHD Treatments: Evidence-Based Options

    Natural ADHD Treatments: Evidence-Based Options

    The search for natural alternatives to pharmaceutical treatments is a growing trend across many medical conditions, and ADHD is no exception. Although stimulant medications remain the gold standard for ADHD management, boasting large effect sizes, they are not without potential risks and side effects. This raises an important clinical question: are there evidence-based natural options that could serve either as primary therapies or as adjunctive treatments in ADHD? Exploring these alternatives could offer valuable strategies for patients and families seeking safer, well-tolerated interventions.

    1. Hirayama et al., 2014 (Phosphatidylserine alone)

    • Population: 36 children (6–12 years) with ADHD
    • Dose: 200 mg/day PS
    • Duration: 15 weeks
    • Main outcomes: ADHD symptoms (teacher ratings), auditory memory

    Reported effect:

    • They did not directly report Cohen’s d, but they reported statistically significant differences between PS and placebo groups on ADHD symptom scores.
    • Based on the mean differences and standard deviations reported:

    Estimated effect size:
    → Cohen’s d ≈ 0.5–0.6 (moderate effect size)

    ✅ Interpretation: A medium, meaningful clinical effect, but not huge like you’d expect with stimulants (where d ~0.8–1.2).

    2. Manor et al., 2012 (Phosphatidylserine + Omega-3 Fatty Acids)

    • Population: 200 children with ADHD symptoms (formal diagnosis not always required)
    • Dose: 300 mg PS + 120 mg EPA + 80 mg DHA daily
    • Duration: 15 weeks
    • Main outcomes: ADHD symptomatology, impulsivity, emotional regulation

    Reported effect:

    • Statistically significant improvements over placebo.
    • Again, they didn’t directly report Cohen’s d, but they provided enough statistical info to estimate.

    Estimated effect size:
    → Cohen’s d ≈ 0.3–0.5 depending on the specific symptom cluster.

    ✅ Interpretation: Small to moderate effect. (Closer to small-to-medium than medium.)

    StudyPopulationInterventionKey Outcome
    Hirayama 2014ADHD kids (n=36)200 mg PS/dayImproved attention & memory
    Manor 2012Kids with ADHD symptoms (n=200)300 mg PS + 200 mg omega-3sReduced impulsivity, improved emotional regulation

    🧠 Clinical Bottom Line:

    • Phosphatidylserine alone → moderate effect on ADHD symptoms (especially attention and memory).
    • PS + Omega-3 → small to moderate effect, mainly helping impulsivity and emotional regulation.
    • Better tolerated than traditional ADHD meds but obviously less potent.

    👉 They could be considered in mild ADHD cases, in parents preferring “natural” options, or as adjuncts to other therapies.

  • Why CBT Reigns as the Top Therapy for Mental Health

    Why CBT Reigns as the Top Therapy for Mental Health

    🧠💡 CBT Confirmed—Again: Landmark Meta-Analysis Reinforces Clinical Value Across Diagnoses
    A massive meta-analysis in JAMA Psychiatry (2025) reaffirms what many of us observe in day-to-day care: Cognitive Behavioral Therapy (CBT) is one of the most effective, versatile, and enduring treatments for adult psychiatric conditions.

    🔬 Study at a Glance

    • Pooled data from hundreds of RCTs
    • Assessed CBT’s efficacy across depression, anxiety disorders, PTSD, and eating disorders
    • Found significant, lasting effects across diagnostic categories
    • Highlighted condition-specific variation in effect sizes, but overall CBT consistently outperformed inactive controls

    📚 Real-World Relevance
    Imagine a patient with chronic panic disorder who’s failed two SSRI trials and prefers non-pharmacologic interventions. CBT remains a frontline solution—equally relevant for the young adult with bulimia or the veteran with PTSD. These aren’t just data points—they’re the cases we see every day.

    🔄 How Does CBT Stack Up Against Other Therapies?
    While the study primarily focused on CBT, it reinforces existing literature suggesting that CBT often matches or outperforms alternative modalities like psychodynamic therapy or interpersonal therapy in short-term efficacy—especially when structure, time-limited treatment, and measurable goals are critical.

    🛠 Implications for Clinical Practice
    ✅ Why prioritize CBT?

    • It’s highly adaptable
    • Supported across diverse populations
    • Scalable via group therapy, digital tools, and telehealth

    🚧 Barriers to Access:

    • Limited availability of trained therapists
    • Insurance coverage gaps
    • Patient preference for “talk therapy” without structure

    ✅ Strategies to Overcome Them:

    • Integrate CBT-informed principles into brief med management visits
    • Refer to digital CBT platforms when face-to-face access is limited
    • Advocate for reimbursement parity and expanded training programs

    📎 Bottom Line
    This study isn’t just academic—it’s a call to action. Prioritizing CBT in treatment planning can lead to better outcomes, broader reach, and more durable recovery. As clinicians, it’s on us to ensure our systems support its accessibility.

    📖 Full Article:
    https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2832696

  • 💊 Methylene Blue: Science-Based Hope or Hype in a Bottle? 💙

    💊 Methylene Blue: Science-Based Hope or Hype in a Bottle? 💙

    As someone who supports thoughtful use of complementary and alternative medicine, I absolutely believe that compounds like SAMe or St. John’s Wort can offer meaningful benefits—when used appropriately and supported by evidence. But with the rise of anti-aging influencers, we’re seeing a familiar pattern: mechanistically promising compounds getting pushed far ahead of the science.

    Methylene Blue is a perfect example.

    🧬 Mechanistic appeal:

    • Enhances mitochondrial respiration
    • Acts as a redox mediator to reduce oxidative stress
    • May support autophagy and protein homeostasis
    • Studied for cognitive enhancement and neuroprotection

    Sounds great on paper—and some early research is encouraging. But…

    ⚠️ Here’s the caution:

    • Most data is from animal studies or in vitro experiments
    • Human trials for cognitive or anti-aging outcomes are small, inconsistent, and early-stage
    • Long-term safety at “biohacker” doses remains largely untested

    Many people are understandably drawn to the promise of longer, healthier lives, but often at the cost of embracing interventions before we truly understand their risks, benefits, or limitations.

    Even if the science makes theoretical sense, biology doesn’t always behave the way our models predict.

    Let’s stay open—but also skeptical. Not everything that sounds too good to be true ends up being true.

  • RFK Jr. Claims He’ll Identify the Cause of Autism by September

    RFK Jr. Claims He’ll Identify the Cause of Autism by September

    In a bold statement this week, Robert F. Kennedy Jr. announced that he will reveal the definitive cause of autism by September. Kennedy, a longtime critic of childhood vaccine programs, did not provide specific scientific details or a research plan, but implied that his administration would prioritize transparency and independent investigations into the condition’s origins.

    The claim has sparked immediate controversy. Autism is a complex neurodevelopmental condition with a strong genetic foundation and a wide range of potential environmental influences—none of which have yielded a singular, definitive cause. The scientific consensus, built over decades of rigorous research, continues to support a multifactorial model rather than a simplistic explanation.

    Many highly intelligent and dedicated scientists have spent years studying autism without identifying a single, unifying cause. One of the recurring issues that arises when politics intersects with science is a resistance to the idea that these are nuanced, multifaceted conditions. It’s not the most satisfying explanation—but it is consistent with the best evidence we have. My fear is that this type of investigation, under political pressure, could prematurely identify a false causal agent—such as vaccines—and reignite a harmful narrative that has already been thoroughly debunked.

    Kennedy’s history of promoting vaccine-autism links adds further concern. The CDC, WHO, and a vast body of peer-reviewed research have all concluded there is no credible evidence connecting vaccines to autism. Suggesting otherwise not only undermines public trust in science and medicine—it risks the health of entire communities by fueling vaccine hesitancy.

    For families and individuals affected by autism, the promise of discovering its origins is understandably compelling. But it’s critical that we approach that pursuit with scientific integrity, not political expediency.

  • 🧠 Esketamine + Antidepressants in TRD: Does the Combo Matter?

    🧠 Esketamine + Antidepressants in TRD: Does the Combo Matter?

    📢 New data from a real-world study of 50,000+ patients with treatment-resistant depression (TRD) published in JAMA Psychiatry:

    📌 Study Question:
    Does combining esketamine with an SSRI or SNRI affect long-term outcomes in TRD?

    📊 Key Findings (5-Year Follow-Up):

    • ✅ Esketamine + SNRI:
       ↘️ Lower all-cause mortality
       ↘️ Fewer hospitalizations
       ↘️ Reduced depressive relapse
    • ✅ Esketamine + SSRI:
       ↘️ Lower incidence of suicide attempts
    • 🔒 Overall: Low rates of adverse outcomes in all groups

    💡 Clinical Implications:

    • Not all combinations are equal—pairing matters.
    • Esketamine + SNRI may be preferred for reducing relapse/mortality
    • Esketamine + SSRI may be considered in patients at risk for suicide
    • Personalized treatment decisions can enhance outcomes in TRD

    🔍 More than symptom relief—it’s about survival, stability, and safety.

  • 🧠 New Research Alert! 🧠

    🧠 New Research Alert! 🧠

    A study in JAMA Psychiatry explores how functional MRI (fMRI) biomarkers can help distinguish major depressive disorder (MDD) 😔 from healthy individuals. Researchers found that regional homogeneity (ReHo) patterns in the brain are a more reliable marker for MDD than traditional structural MRI 🏗️.

    🔬 Why does this matter?
    👉 Better Diagnostics: fMRI could lead to more objective ways to diagnose depression, reducing reliance on self-reporting.
    👉 Early Detection: One day, brain scans 🏥 might help identify people at risk before symptoms fully develop.
    👉 Personalized Treatment: Understanding individual brain patterns could help guide targeted interventions like therapy or medication.

    Could brain scans be the future of depression diagnosis? 🤔 Drop your thoughts below! ⬇️

    📖 Read more: jamanetwork.com

  • 🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

    🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

    A recent study published in Frontiers in Psychiatry reveals that individuals using antidepressants experienced notable weight gain over a six-year period.​

    Key Findings:

    • Increased Weight Gain:​
      • Participants who used antidepressants showed an average weight increase of approximately 2% of their baseline body weight compared to non-users.​
    • Higher Obesity Risk:​
      • Those without obesity at the study’s start had double the risk of becoming obese if they used antidepressants throughout the six years.​

    Implications:

    With the widespread use of antidepressants and the global obesity epidemic, integrating weight management and metabolic monitoring into depression treatment plans is crucial.​

    link: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1464898/full

  • Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

    Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

    A devastating blow to public health: More than $12 billion in federal grants—funding that supported infectious disease tracking, mental health services, addiction treatment, and other critical programs—has been canceled as part of recent federal budget cuts.

    These cuts threaten early detection of outbreaks, access to psychiatric care, and lifesaving addiction treatment programs—all areas where we, as physicians, see the impact daily.

    Key Areas Affected:

    🚨 Infectious Disease Surveillance – Reduced ability to track emerging threats like COVID-19, flu, and antibiotic-resistant infections.
    🧠 Mental Health Services – Fewer resources for crisis response teams, community mental health centers, and psychiatric services.
    💉 Addiction Treatment – Less funding for MAT (medication-assisted treatment) and harm reduction programs at a time when overdose rates remain high.
    🏥 Public Health Preparedness – Cuts to pandemic readiness and emergency response training for healthcare workers.

    What Can We Do?

    🔹 Advocate – Contact legislators, professional organizations (APA, AMA, ACP), and demand restoration of funding.
    🔹 Educate – Inform patients and communities about how these cuts impact their care.
    🔹 Mobilize – Work with hospital leadership and local organizations to find alternative funding sources.
    🔹 Collaborate – Strengthen interprofessional partnerships to sustain services despite budget constraints.

    We’ve seen what happens when public health is underfunded—it costs more lives and more money in the long run. We can’t afford to be silent.

  • Olanzapine vs. Quetiapine for Stimulant Psychosis: Is One the Clear Winner?

    Olanzapine vs. Quetiapine for Stimulant Psychosis: Is One the Clear Winner?

    There is limited high-quality randomized controlled trial (RCT) evidence specifically comparing Zyprexa (olanzapine) or Seroquel (quetiapine) for the treatment of stimulant-induced psychosis (SIP), including cocaine-induced psychosis. However, some RCTs and observational studies provide useful insights:

    Olanzapine (Zyprexa)

    • RCT Evidence:
      • A 2022 meta-analysis of antipsychotic treatments for stimulant-induced psychosis included olanzapine and found it to be effective in reducing positive psychotic symptoms, often comparable to haloperidol but with a better side effect profile (less extrapyramidal symptoms) 11.
      • A double-blind RCT comparing olanzapine vs. haloperidol in methamphetamine-induced psychosisfound that both were effective at reducing PANSS (Positive and Negative Syndrome Scale) scores, but olanzapine was associated with better tolerability 22.
      • Another RCT in methamphetamine-induced psychosis compared olanzapine and risperidone, showing similar efficacy but better tolerability with olanzapine 33.

    Quetiapine (Seroquel)

    • RCT Evidence:
      • A small RCT in methamphetamine-induced psychosis found that quetiapine was effective but tended to require higher doses to achieve symptom resolution 44.
      • A retrospective study on cocaine-induced psychosis suggested that quetiapine may help reduce symptoms, but data is weaker compared to olanzapine or risperidone 55.
      • Quetiapine has also been studied as an option for reducing cocaine cravings, but results are mixed and it is generally less preferred for acute agitation compared to faster-acting options like olanzapine.

    Head-to-Head Comparison

    There is no direct RCT comparing olanzapine vs. quetiapine for stimulant-induced psychosis, but based on available data:

    • Olanzapine is generally preferred for acute agitation and psychosis because of its faster onset and greater D2 blockade.
    • Quetiapine may be useful in milder cases or for individuals needing sedation, but higher doses are often required.

    Clinical Implications

    • For acute stimulant-induced psychosis, olanzapine (5–10 mg IM or PO) is a common first-line option due to rapid onset and favorable side effect profile.
    • Quetiapine (200–400 mg PO) can be considered, particularly for patients needing sedation or those with comorbid conditions like bipolar disorder.
    • Other antipsychotics with strong evidence include risperidone and haloperidol (though the latter has more extrapyramidal risk).

    After reviewing the available literature, direct randomized controlled trials (RCTs) comparing olanzapine (Zyprexa) and quetiapine (Seroquel) for stimulant-induced psychosis (SIP), including cocaine-induced psychosis, remain scarce. However, some studies provide relevant insights:

    Olanzapine (Zyprexa):

    • Efficacy: A randomized, double-blind trial compared olanzapine and haloperidol in patients with amphetamine-induced psychosis. Both medications effectively improved psychotic symptoms in the short term, with olanzapine showing a faster onset of action.

    Quetiapine (Seroquel):

    • Efficacy: A double-blind RCT compared haloperidol and quetiapine for methamphetamine-induced psychosis. While both medications reduced psychotic symptoms, quetiapine appeared to have a more favorable profile in reducing certain symptoms over time. 

    Indirect Comparisons:

    • First-Episode Psychosis: A 52-week randomized, double-blind study evaluated olanzapine, quetiapine, and risperidone in early psychosis patients. All three antipsychotics demonstrated comparable effectiveness, as indicated by similar rates of treatment discontinuation.

    Conclusion:

    While direct RCT evidence comparing olanzapine and quetiapine specifically for stimulant-induced psychosis is limited, existing studies suggest that both medications are effective in managing such conditions. Olanzapine may offer a faster onset of symptom relief, whereas quetiapine might present a more favorable side effect profile. Clinical decisions should be individualized, considering factors such as patient history, specific symptomatology, and potential side effects.

  • Can Creatine Boost Therapy for Depression? New Study Says Maybe!

    Can Creatine Boost Therapy for Depression? New Study Says Maybe!

    A recent 8-week double-blind, randomized, placebo-controlled trial investigated whether oral creatine monohydrate (5g/day) could enhance the effects of cognitive-behavioral therapy (CBT) in treating major depressive disorder (MDD)—especially in under-resourced areas where access to treatment is limited.

    🔬 Why Does This Matter?
    While CBT is a gold-standard therapy for depression, many patients do not achieve full remission. This study explored whether creatine—widely used for muscle and brain energy metabolism—could provide an extra boost to treatment.

    🧠 Key Findings:
    ✅ Participants receiving creatine + CBT had greater reductions in depression symptoms (measured by the Hamilton Depression Rating Scale) compared to those receiving placebo + CBT
    ✅ Reported improvements in mood, energy levels, and cognitive function
    ✅ Creatine was well-tolerated, with no significant safety concerns
    ✅ CBT was delivered once weekly by trained therapists

    ⚠️ Study Limitations:
    🔹 Small sample size—larger studies are needed to confirm these findings
    🔹 Short trial duration—long-term effects are still unknown
    🔹 Study population—results may not generalize to all individuals with MDD

    💡 What’s Next?
    If larger studies confirm these results, creatine could become an accessible, affordable adjunct to therapy, particularly in communities with limited mental health resources.

    What do you think? Could a common fitness supplement help improve mental health? Let’s discuss! ⬇️

    link to study: https://www.sciencedirect.com/science/article/pii/S0924977X24007405